Osteosarcoma
Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole
February 21, 2018This phase 2 study sought to determine whether concurrent pantoprazole would improve cisplatin-induced ototoxicity and nephrotoxicity in younger patients with osteosarcoma.
Defects in DNA Imprinting Affect Development and Progression of Childhood Osteosarcoma
February 23, 2016Osteosarcoma in children may be impacted by a defect in DNA imprinting that also occurs in their biological parents. These imprinting defects may be predictive of survival outcomes.
Canine osteosarcoma samples identify drivers of metastasis in pediatric bone cancer
April 30, 2013Researchers presenting at the American Association for Cancer Research Annual Meeting 2013 used easily available canine osteosarcoma samples to discover a novel protein that governs metastasis and chemoresistance in pediatric osteosarcoma.
Delayed methotrexate clearance
August 24, 2012What are some common reasons for delayed methotrexate clearance after a 24-hour infusion?
Protein may predict chemotherapy response in osteosarcoma
July 20, 2012The expression of the P16 protein, which inhibits cell growth, may be useful for predicting how osteosarcoma will respond to chemotherapy.
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |